KBC Group’s Amicus Therapeutics FOLD Stock Holding History

KBC Group’s Portfolio FOLD Stock Details FOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$147K	Hold	10,154	–	–	﹤0.01%	1104
2025 Q4	$145K	Hold	10,154	–	–	﹤0.01%	1060
2025 Q3	$80K	Hold	10,154	–	–	﹤0.01%	1395
2025 Q2	$58K	Hold	10,154	–	–	﹤0.01%	1533
2025 Q1	$83K	Hold	10,154	–	–	﹤0.01%	1586
2024 Q4	$96K	Buy	10,154 +3,120	+44%	+$32.4K	﹤0.01%	1587
2024 Q3	$75K	Buy	7,034 +204	+3%	+$2.22K	﹤0.01%	1476
2024 Q2	$68K	Buy	6,830 +1,806	+36%	+$18.5K	﹤0.01%	1432
2024 Q1	$59K	Hold	5,024	–	–	﹤0.01%	1452
2023 Q4	$71K	Hold	5,024	–	–	﹤0.01%	1281
2023 Q3	$61K	Buy	+5,024	New	+$64.8K	﹤0.01%	1302
2019 Q4	–	Sell	-6,860	Closed	-$55K	–	1515
2019 Q3	$55K	Buy	6,860 +6,240	+1,006%	+$67.7K	﹤0.01%	1383
2019 Q2	$8K	Hold	620	–	–	﹤0.01%	1442
2019 Q1	$8K	Hold	620	–	–	﹤0.01%	1401
2018 Q4	$6K	Hold	620	–	–	﹤0.01%	1298
2018 Q3	$7K	Hold	620	–	–	﹤0.01%	1383
2018 Q2	$10K	Hold	620	–	–	﹤0.01%	1281
2018 Q1	$9K	Hold	620	–	–	﹤0.01%	1264
2017 Q4	$9K	Buy	+620	New	+$8.52K	﹤0.01%	1248

Other funds holding FOLD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

KBC Group's FOLD Position: Q1 2026 in Review

KBC Group held its Amicus Therapeutics (FOLD) position steady in Q1 2026 at 10,154 shares worth $147K. The position accounts for ﹤0.01% of the portfolio, ranked #1104.

KBC Group first reported a position in FOLD in Q4 2017 and has held it in 19 quarters since. 298 funds tracked by Wall St. Rank hold FOLD as of Q1 2026.

KBC Group held 10,154 shares of Amicus Therapeutics worth $147K as of Q1 2026.
KBC Group left its Amicus Therapeutics share count unchanged in Q1 2026.
Amicus Therapeutics made up ﹤0.01% of KBC Group's portfolio in Q1 2026, its #1104 holding.
KBC Group first reported a position in Amicus Therapeutics in Q4 2017 and has held it in 19 quarters since.
298 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2026.

Based on KBC Group's 13F filing for Q1 2026, filed 7 May 2026.